Company Description: Founded in 2018 and headquartered in Derio (Bizkaia), Mikrobiomik is a bio-pharmaceutical company created to conduct research, develop and manufacture of medicines based on the human microbiome. The Company’s aim is to market in 2025 the first biological medicine based on intestinal microbiota in Europe. MBK-01 is a biological medicine with FSPIM® (Full spectrum and purified intestinal microbiota) technology that is available as lyophilized oral capsules of intestinal microbiota, designed for treating Clostridioides Difficile, in a simple dose of four capsules. MBK-01 is also aimed at various indications at different stages of development. Production will be through internal sourcing and commercialization will be through license agreements. We are in conversations with several pharmaceutical companies with the aim of licensing MBK-01 for commercialization. Formulation and manufacturing/quality GMP (Good Manufacturing Procedures) procedures protected under trade secret with blockchain technology. Mikrobiomik team is integrated by 19 professionals, with experience in the different fields to cover the necessary knowledge of the production chain. The Company’s shareholding structure is composed of 5 Family Offices, which own 51%, 3 individual investors, which own 14%, and 2 public institutions, which own 36%. The main shareholder holds a 33% of the capital